BRIEF-Astrazeneca Says Imfinzi Combo Shows Unprecedented Survival In Unresectable Liver Cancer

AstraZeneca PLC: * ASTRAZENECA PLC - IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC

* ASTRAZENECA - A SINGLE PRIMING DOSE OF TREMELIMUMAB PLUS IMFINZI EVERY FOUR WEEKS REDUCED RISK OF DEATH BY 22% IN HIMALAYA PHASE III TRIAL * ASTRAZENECA - COMBINATION ALSO SHOWED NO INCREASE IN SEVERE LIVER TOXICITY AND FEWER DISCONTINUATIONS DUE TO TREATMENT-RELATED ADVERSE EVENTS VERSUS. SORAFENIB Source text for Eikon: Further company coverage: